Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology
-- Cash and other short-term assets of US$242.1 million as of December 31, 2022
- -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
-- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business. - Furthermore, I am immensely optimistic with our new business strategy in precision oncology.
- Prenetics is focusing its business strategy to genomics and precision oncology, and is dedicated to transforming patients' care through advanced genomic and molecular technologies.
- -- Adjusted EBITDA was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.